Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab deruxtecan (I-DXd) in Advanced Esophageal Squamous Cell Carcinoma (KEYMAKER-U06 Substudy 06F)
NCT07405151Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 11
01
Overview
A Phase 2 trial of ifinatamab deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Mar 2026; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07405151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405151.